ESTRO 2024 - Abstract Book

S1077

Clinical - Gynaecology

ESTRO 2024

[3] M. D. Stein, J. H. T. G. Fregnani, C. Scapulatempo-Neto, and A. Longatto-Filho, “Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study,” Diagnostic Pathology, vol. 10, no. 1, Jan. 2015, doi: https://doi.org/10.1186/s13000-014-0231-7.

[4] S. V. Poflee and J. K. Bhatia, “Cervical cytology: Radiation and other therapy effects,” Cytojournal, vol. 19, p. 32, Apr. 2022, doi: https://doi.org/10.25259/cmas_03_12_2021.

[5] L. Elit, A. W. Fyles, M. C. Devries, T. K. Oliver, and M. Fung-Kee-Fung, “Follow-up for women after treatment for cervical cancer: A systematic review,” Gynecologic Oncology, vol. 114, no. 3, pp. 528–535, Sep. 2009, doi: https://doi.org/10.1016/j.ygyno.2009.06.001. [6] P. Morice et al., “Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery–radiation therapy,” Annals of Oncology, vol. 15, no. 2, pp. 218–223, Feb. 2004, doi: https://doi.org/10.1093/annonc/mdh050. [7] Seiji Mabuchi et al., “Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy,” Archives of Gynecology and Obstetrics, vol. 286, no. 1, pp. 179–185, Jan. 2012, doi: https://doi.org/10.1007/s00404-012-2235-4.

2355

Mini-Oral

Biological treatment evaluation in clinical thermoradiotherapy applied for cervical cancer patients

H. P. Kok, T. D. Herrera, J. Crezee

Amsterdam UMC, Radiation Oncology, Amsterdam, Netherlands

Purpose/Objective:

Hyperthermia therapy involves heating tumours to 39-43°C for ~1h. This very potent radiosensitizer is clinically applied to several tumour sites to enhance treatment outcome with typically ~15% increase in tumour control without significantly enhancing side effects. Hyperthermia treatment quality is usually evaluated by thermal (dose) parameters, calculated from continuous on-line temperature measurements. However, the effectiveness of hyperthermia combined with radiotherapy (thermoradiotherapy) not only depends on the achieved tumour temperatures, but also on the time interval between both treatment modalities. This time interval is influenced by logistics. Therefore, the concept of biological modelling using an extended LQ-model has been proposed to capture both temperature and time interval in a dose parameter. This way an equivalent radiation dose (EQD RT ) can be calculated, i.e. the dose needed with radiation alone to realize the same effect as in the combined treatment. So far, biological modelling for thermoradiotherapy was limited to treatment planning studies and not used for evaluation of actual clinical treatments. In this work we applied biological modelling for clinical treatment evaluation of a cohort of cervical cancer patients treated with radiotherapy plus hyperthermia by calculating the EQD RT . Subsequent analyses evaluated the impact of optimal and suboptimal logistics on EQD RT .